All
Aidixi Plus Bacillus Calmette-Guérin Effective in Bladder Cancer
Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.
Lingering Stress After Follicular Lymphoma Remission is a Challenge
Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue to weigh heavily on me.
CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer
CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study.
Larger Tumor Size Linked to Higher Mortality Risk in Brain Cancer
Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.
SENTI-202 Shows Positive Preliminary Data in Acute Myeloid Leukemia
A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia.
An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC
The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer.
Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer
Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer.
TAR-200 Shows High Response Rates in Bladder Cancer Subset
TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study.
A Fellow Cancer Survivor Gives Me a Useful Message
A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.
FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer
The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.
FDA Fast Tracks INX-315 for Tough-to-Treat Ovarian Cancer
INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.
SIRT With 90Y Resin Microspheres Provides Benefit in GIST Liver Metastases
SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver metastases resistant to TKI therapy.
Alternating Glivec and Stivarga Doesn't Improve Advanced GIST Outcomes
Alternating between Glivec and Stivarga therapy didn't impact survival outcomes; it led to more toxicity and discontinuations in patients with GIST.
Breast MRI Offers Sensitive Imaging for High-Risk and Diagnosed Patients
Breast MRI helps doctors detect disease in newly diagnosed and high-risk patients without replacing mammograms, according to an expert.
Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer
Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety.
How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer
I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference.
TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups
TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.
Zongertinib Elicits Responses in HER2-Mutant NSCLC
Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer.
How an Advocate Unites Voices to Guide MPN Research Decisions
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Healer, Mentor and Leader
Reflecting upon my relationship with Jill over the past 25 years, I am in awe of all she has accomplished.
Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models
HT-KIT, a novel targeted therapy for GIST, demonstrated the ability to reduce tumor burden in humanized mouse models and induce tumor cell death.
FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors
Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025.
Crafting an Individual Treatment Plan for Patients With Prostate Cancer
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Commitment to Patients Is Driven by a Lasting Promise
Mikela Pettigrew, B.S.N., RN, OCN,, exemplifies extraordinary compassion and dedication. Every day, she fulfills a promise she made as a young caregiver.
Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care
Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer following cystectomy and chemo.
New Options for ER+ Breast Cancer Spotlighted at Patient Event
Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and provided subsequent updates.
A Digital Detox for the Soul with Lynch Syndrome
Unplugging from digital noise helped me find peace, clarity and room for growth during a season of emotional and mental renewal.
Decipher Prostate Test Now Available for Metastatic Prostate Cancer
Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.
Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC
Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.
